Core Viewpoint - The news highlights the existence of a black market for counterfeit health products that appear to be imported but are actually produced domestically, exploiting loopholes in regulations and misleading consumers [1][2][3]. Group 1: Industry Practices - Some companies, like Jiangsu Qizhen Tang Biotechnology Co., claim to provide a full suite of services for cross-border health product sales, including the establishment of overseas companies and trademark purchases [2]. - Anhui Quankang Pharmaceutical Co. has registered a company in Hong Kong to create a facade of legitimacy for their products, which are still produced domestically [2]. - Shandong Dongying Yinuokang Pharmaceutical Co. produces health product capsules domestically and then ships them abroad for packaging, making it difficult for authorities to trace the origin of the products [3]. Group 2: Regulatory Environment - The current lack of clear regulations regarding cross-border health products allows companies to operate with significant flexibility in terms of cost, quality, and marketing [2]. - Legal consequences for false advertising and the production of counterfeit drugs are outlined in the Criminal Law, with penalties ranging from fines to imprisonment depending on the severity of the offense [3].